Clinical Trials
58 trialsPIPO
Vall d'Hebron Institute of Oncology
ICI-Vasc
University Hospital, Rouen
Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
Peking University People's Hospital
HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion
Peking University
Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma
Zhujiang Hospital
Immune-Related Adverse Events After Cancer Immunotherapy and Safety of Treatment Rechallenge
Peking Union Medical College Hospital
A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
G/GEJ
Fudan University
Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON)
Duke University
INTER-AUTENTIC
Hospital Universitario Araba
Survival Analysis and Prognostic Biomarker Exploration of Postoperative Adjuvant Therapy Patterns in Patients With Non-small Cell Lung Cancer After Neoadjuvant Immunotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
TASK-01-RW
Fudan University
Proposal of a Novel Model for Identifying Complete Response in dMMR Colon Cancer Following Neoadjuvant Immunotherapy
Sun Yat-sen University
An Observational Clinical Study of Stereotactic Radiotherapy for Advanced Non-Small Cell Lung Cancer With Stable Disease After PD-1 Inhibitor Treatment
Xinqiao Hospital of Chongqing
Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Conversion Surgery After Target Therapy or Immunotherapy in Stage IV Gastric Cancer
Samsung Medical Center
Analysis of Drug Resistance in Immune Checkpoint Inhibitors of Non-small Cell Lung Cancer
Shanghai Chest Hospital
FECONDE
IRCCS San Raffaele
AUTENTIC
Hospital Universitario Araba
Clinical Application of PD-1 Inhibitor in Colorectal Cancer for Improving Survival
Sun Yat-sen University
CCGLC-001
Tongji Hospital
Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy
Peking University Cancer Hospital & Institute
A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors
Asan Medical Center
Impact of Concomitant Use of Steroids and Immune-Checkpoint Inhibitors on Survival Outcomes in NSCLC Patients
Seoul National University
Glycoprotein in Immunotherapy Response and Efficacy Prediction of Lung Cancer
Shanghai Chest Hospital
HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC
First Hospital of China Medical University
Gastric Cancer Complicated With Bleeding
Peking University Third Hospital
GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC
Universitaire Ziekenhuizen KU Leuven
A Real-World Study of Neoadjuvant/Conversion Therapy for Locally Advanced or Metastatic Gastric Cancer
Wuhan University
CCGLC-008
Tongji Hospital
Observational Study on the Sensitivity of Neoadjuvant Immunotherapy in Early Triple-Negative Breast Cancer
Shandong University
CREATE
Hunan Province Tumor Hospital
EXIT
Groupe Hospitalier Pitie-Salpetriere
Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy
Chinese PLA General Hospital
Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC
Hunan Cancer Hospital
Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer
Hunan Cancer Hospital
Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer
Hunan Cancer Hospital
Correlation Between Pre-transplant ICI Exposure and Post-transplant Graft Rejection
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular Carcinoma
Sun Yat-sen University
Radiotherapy Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of NSCLC Patients With Symptomatic Brain Metastases
Xiangya Hospital of Central South University
Single-center, Prospective Cohort Study of PD-1 Inhibitors on Clinical Outcomes of Carotid Plaques in Tumor Patients
Second Affiliated Hospital, School of Medicine, Zhejiang University
TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT
Sun Yat-sen University
Postoperative Adjuvant Therapy of HCC Based on PD-1
Tongji Hospital
HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma
Sun Yat-sen University
Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC
Tongji Hospital
The Prediction Biomarkers of Survival Outcome for Severe Immune-related Hepatitis
Hunan Province Tumor Hospital
Multi-center Observational Study on the Progression of Atherosclerotic Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up
Second Affiliated Hospital, School of Medicine, Zhejiang University